Stephen Brannan, MD

Xanomeline-trospium targets muscarinic receptors for schizophrenia relief with fewer side effects, and early data suggest cognitive gains.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.